Flash Finance

Mankind Pharma LimitedMANKINDCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹2,275.50
MCap ₹93,988 Cr · P/E 45.5
Mankind Pharma Limited — Stock analysis & AI research Mankind Pharma Limited — Seasonality — best & worst months Mankind Pharma Limited — Technical indicators & charts Mankind Pharma Limited — Technical setup — score, trend, support & resistance Mankind Pharma Limited — Triple Top pattern forming Mankind Pharma Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 High Promoter Holding Stocks📋 Mid Cap Stocks List 📈 SuperTrend Bearish Signal 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹4,031 Cr
Sales · Jun 2026
+12.9% YoY
₹1,056 Cr
Operating Profit · Jun 2026
+24.7% YoY
26.2%
OPM % · Jun 2026
+10.5% YoY
₹574 Cr
Net Profit · Jun 2026
+29.1% YoY
₹13.76
EPS · Jun 2026
+29.6% YoY

📝 Mankind Pharma Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Mankind Pharma Limited reported revenue of ₹4,031 crore for the quarter ended June 2026 (Q1 FY27), up 12.9% from ₹3,570 crore in the same quarter last year, and up 17.1% sequentially over the March 2026 quarter.

Net profit rose 29.1% year-on-year to ₹574 crore, from ₹445 crore. Earnings per share (EPS) came in at ₹13.76.

Operating profit stood at ₹1,056 crore — an operating margin (OPM) of 26.2%, compared with 23.7% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Mankind Pharma Limited posted revenue of ₹14,278 crore, a growth of 16.3% over FY25, with a net profit of ₹1,938 crore (down 3.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹14,738 crore with a net profit of ₹2,067 crore.

Valuation snapshot

At the current price of ₹2,275.50, MANKIND has a market capitalisation of ₹93,988 crore and a trailing P/E of about 45.5.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 10th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.62%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 15.56%, public shareholders 2.45% of Mankind Pharma Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹93,988 Cr
Current Price ?
₹2,275.5
P/E ?
45.47above ind
Industry P/E ?
35.00
P/B ?
5.77
P/S ?
6.38
P/FCF ?
39.38
Enterprise Value ?
₹100,300 Cr
EV/EBITDA ?
26.21
PEG ?
2.67
Earnings Yield ?
2.9%
Dividend Yield ?
0.04%
Profitability & Returns
Sales (TTM) ?
₹14,738 Cr
OPM ?
26.0%
Profit after tax (TTM) ?
₹2,067 Cr
EPS (TTM) ?
₹50.05
ROCE ?
14.0%
ROE ?
12.7%
ROA ?
7.4%
Growth
Sales — latest qtr ?
₹4,031 Cr
PAT — latest qtr ?
₹574 Cr
YoY qtr sales growth ?
12.9%
YoY qtr profit growth ?
29.1%
Sales growth (3y) ?
18%
Sales growth (5y) ?
18%
Profit growth (3y) ?
17%
Profit growth (5y) ?
11%
Financial Health
Debt ?
₹6,312 Cr
Debt to Equity ?
0.39
Interest Coverage ?
4.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.62%
Change in promoter holding ?
-0.05%
Pledged percentage ?
N/A
Market
Return 3 months ?
-8.4%
Return 6 months ?
7.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 2,0532,5792,7082,6072,4412,8933,0773,2303,0793,5703,6973,5673,4434,031 +12.9% +17.1%
Operating Profit 4176556836075916828508306838479219199301,056 +24.7% +13.6%
Other Income 5063637095105109772548092769445 -43.7% -52.1%
Interest 56999117221191171170157142110 -35.6% -22.5%
Depreciation 858796110105108106192231219222223223226 +3.2% +1.2%
Profit Before Tax 377624641562572668849497515540624509659769 +42.4% +16.8%
Net Profit 294494511460477543659385425445520414559574 +29.1% +2.7%
EPS 7.1312.1512.5111.3311.7613.3916.319.4510.2010.6212.399.9013.4313.76 +29.6% +2.5%
OPM % 20.3% 25.4% 25.2% 23.3% 24.2% 23.6% 27.6% 25.7% 22.2% 23.7% 24.9% 25.8% 27.0% 26.2% +10.5% -3.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹12,279 Cr ₹14,278 Cr ₹14,738 Cr +16.3%
Operating Profit ₹3,045 Cr ₹3,618 Cr ₹3,827 Cr +18.8%
OPM % 24.80% 25.34% 25.97% +2.2%
NPM % 16.38% 13.57% 14.03% -17.2%
Other Income ₹545 Cr ₹342 Cr ₹307 Cr -37.3%
Depreciation ₹637 Cr ₹886 Cr ₹893 Cr +39.2%
Interest ₹429 Cr ₹640 Cr ₹579 Cr +48.9%
EBIT ₹2,408 Cr ₹2,731 Cr ₹2,934 Cr +13.4%
PBT ₹2,530 Cr ₹2,333 Cr ₹2,561 Cr -7.8%
Tax ₹514 Cr ₹295 Cr ₹394 Cr -42.7%
Net Profit ₹2,011 Cr ₹1,938 Cr ₹2,067 Cr -3.7%
EPS ₹49.35 ₹46.34 ₹49.48 -6.1%
Material Cost ₹3,681 Cr ₹2,963 Cr ₹3,204 Cr -19.5%
Employee Cost ₹2,706 Cr ₹2,432 Cr ₹2,562 Cr -10.1%
Extraordinary Items ₹-4 Cr ₹107 Cr ₹107 Cr +2556.0%

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 40404141 +0.0%
Reserves 7,3959,32314,29116,259 +13.8%
Borrowings 1702078,5116,312 -25.8%
Other Liabilities 2,0802,3134,8085,468 +13.7%
Total Liabilities 9,68611,88327,65228,080 +1.5%
Fixed Assets 4,2514,54519,00519,093 +0.5%
CWIP 550282826655 -20.7%
Investments 1,3462,5682,0421,985 -2.8%
Other Assets 3,5384,4885,7806,346 +9.8%
Total Assets 9,68611,88327,65228,080 +1.5%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1,8132,1522,4133,121 +29.3%
Cash from Investing Activity -1,052-2,081-12,624-196 +98.4%
Cash from Financing Activity -740510,233-2,953 -128.9%
Net Cash Flow 227722-28 -227.3%
Free Cash Flow 9871,7711,8952,387 +26.0%
CFO/OP 112%103%98%103% +5.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 24304644 -4.3%
Inventory Days 188180219193 -11.9%
Days Payable 12690119121 +1.7%
Cash Conversion Cycle 86120146117 -19.9%
Working Capital Days 3953-28-1 +96.4%
ROCE % 22%26%16%14% -12.5%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 72.67%72.67%72.66%72.66%72.63%72.62% -0.0%
FIIs 13.07%12.83%11.34%10.24%9.45%9.37% -0.8%
DIIs 11.50%11.91%13.26%14.46%15.39%15.56% +1.1%
Public 2.75%2.57%2.75%2.63%2.53%2.45% -3.2%
No. of Shareholders 1,79,5491,70,3471,77,5391,77,6061,66,7151,63,770 -1.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Mankind Pharma Limited's revenue in Q1 FY27?
Mankind Pharma Limited reported revenue of ₹4,031 crore for the quarter ended June 2026 (Q1 FY27), up 12.9% from ₹3,570 crore in the same quarter last year, and up 17.1% sequentially over the March 2026 quarter.
What was Mankind Pharma Limited's net profit in Q1 FY27?
Net profit rose 29.1% year-on-year to ₹574 crore, from ₹445 crore. Earnings per share (EPS) came in at ₹13.76.
What is MANKIND's market capitalisation and P/E ratio?
At the current price of ₹2,275.50, MANKIND has a market capitalisation of ₹93,988 crore and a trailing P/E of about 45.5.
Who owns Mankind Pharma Limited? (shareholding pattern)
As of Sep 2026, promoters held 72.62%, foreign institutional investors (FIIs) 9.37%, domestic institutional investors (DIIs) 15.56%, public shareholders 2.45% of Mankind Pharma Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI